Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382562503> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4382562503 endingPage "26" @default.
- W4382562503 startingPage "26" @default.
- W4382562503 abstract "Aim: Impairment of cholesterol homeostasis is one of the multiple etiopathological mechanisms at the origin of both cardiovascular and neurodegenerative diseases. The PCSK9 protein, known for its role in the degradation of hepatic LDLR and plasma cholesterol regulation, is expressed also in the CNS, where it exacerbates -amyloid neurotoxicity and reduces neuronal cholesterol uptake, suggesting an involvement in AD. This study proposes an in vitro screening of molecules (MR) with inhibitory activity on PCSK9, selecting the best compounds to test their activity on cerebral cell models and their in vivo tolerability. Methods: 30 newly synthesized compounds were tested at increasing concentrations on human hepatoma cells (HepG2) to evaluate their cytotoxicity and efficacy in inhibiting PCSK9. MR-3 was tested on human neuroblastoma cells (SH-SY5Y) overexpressing PCSK9 to assess neurotoxicity and cholesterol uptake. Cytotoxicity was determined through MTT assay; PCSK9 secretion was quantified with an ELISA kit; and radioisotopic techniques measured cholesterol uptake . Three compounds were selected to be tested in vivo on C57BL/6 mice at a dose of 40 mg/Kg for 7 days to evaluate: tolerability with SHIRPA test; plasma lipid profile by ELISA assay; biodistribution in plasma and brain through LC-MS/MS. Results: Among the tested compounds, MR-3, MR-532, MR-533 demonstrated no sign of cytotoxicity and the greatest efficacy on HepG2 cells (IC50=1.7μM; 5.7μM; 6.1μM). Neuronal cholesterol uptake was restored after treatment with MR-3 at 10μM (p<0,05). MR-3, MR-532, and MR-533 exhibited good in vivo tolerability; MR-3 and MR-532 were detected in plasma and brain tissue. Conclusions: Preliminary in vitro screening allowed the identification of MR-3, MR-532, MR-533 as promising PCSK9 inhibitors. The outcome of MR-3 on neuronal cholesterol uptake may suggest a neuroprotective effect to be further investigated. In vivo treatment with selected inhibitors shown absence of toxicity, however, it is necessary to bring proof of efficacy." @default.
- W4382562503 created "2023-06-30" @default.
- W4382562503 creator A5000758972 @default.
- W4382562503 creator A5005036570 @default.
- W4382562503 creator A5005990941 @default.
- W4382562503 creator A5015415923 @default.
- W4382562503 creator A5016372629 @default.
- W4382562503 creator A5027968457 @default.
- W4382562503 creator A5047273885 @default.
- W4382562503 creator A5048439103 @default.
- W4382562503 creator A5053614165 @default.
- W4382562503 creator A5058306074 @default.
- W4382562503 creator A5058919266 @default.
- W4382562503 creator A5061307026 @default.
- W4382562503 creator A5062324284 @default.
- W4382562503 date "2023-04-30" @default.
- W4382562503 modified "2023-10-07" @default.
- W4382562503 title "In vitro and in vivo studies on novel pcsk9 inhibitors as pharmacological approach for the treatment of alzheimer’s disease" @default.
- W4382562503 doi "https://doi.org/10.56095/eaj.v2i1.43" @default.
- W4382562503 hasPublicationYear "2023" @default.
- W4382562503 type Work @default.
- W4382562503 citedByCount "0" @default.
- W4382562503 crossrefType "journal-article" @default.
- W4382562503 hasAuthorship W4382562503A5000758972 @default.
- W4382562503 hasAuthorship W4382562503A5005036570 @default.
- W4382562503 hasAuthorship W4382562503A5005990941 @default.
- W4382562503 hasAuthorship W4382562503A5015415923 @default.
- W4382562503 hasAuthorship W4382562503A5016372629 @default.
- W4382562503 hasAuthorship W4382562503A5027968457 @default.
- W4382562503 hasAuthorship W4382562503A5047273885 @default.
- W4382562503 hasAuthorship W4382562503A5048439103 @default.
- W4382562503 hasAuthorship W4382562503A5053614165 @default.
- W4382562503 hasAuthorship W4382562503A5058306074 @default.
- W4382562503 hasAuthorship W4382562503A5058919266 @default.
- W4382562503 hasAuthorship W4382562503A5061307026 @default.
- W4382562503 hasAuthorship W4382562503A5062324284 @default.
- W4382562503 hasBestOaLocation W43825625031 @default.
- W4382562503 hasConcept C109316439 @default.
- W4382562503 hasConcept C126322002 @default.
- W4382562503 hasConcept C150903083 @default.
- W4382562503 hasConcept C185592680 @default.
- W4382562503 hasConcept C197934379 @default.
- W4382562503 hasConcept C202751555 @default.
- W4382562503 hasConcept C207001950 @default.
- W4382562503 hasConcept C2778163477 @default.
- W4382562503 hasConcept C2778375690 @default.
- W4382562503 hasConcept C2779491297 @default.
- W4382562503 hasConcept C2780072125 @default.
- W4382562503 hasConcept C2780783641 @default.
- W4382562503 hasConcept C2780948078 @default.
- W4382562503 hasConcept C29730261 @default.
- W4382562503 hasConcept C43554185 @default.
- W4382562503 hasConcept C55493867 @default.
- W4382562503 hasConcept C71924100 @default.
- W4382562503 hasConcept C86803240 @default.
- W4382562503 hasConcept C98274493 @default.
- W4382562503 hasConceptScore W4382562503C109316439 @default.
- W4382562503 hasConceptScore W4382562503C126322002 @default.
- W4382562503 hasConceptScore W4382562503C150903083 @default.
- W4382562503 hasConceptScore W4382562503C185592680 @default.
- W4382562503 hasConceptScore W4382562503C197934379 @default.
- W4382562503 hasConceptScore W4382562503C202751555 @default.
- W4382562503 hasConceptScore W4382562503C207001950 @default.
- W4382562503 hasConceptScore W4382562503C2778163477 @default.
- W4382562503 hasConceptScore W4382562503C2778375690 @default.
- W4382562503 hasConceptScore W4382562503C2779491297 @default.
- W4382562503 hasConceptScore W4382562503C2780072125 @default.
- W4382562503 hasConceptScore W4382562503C2780783641 @default.
- W4382562503 hasConceptScore W4382562503C2780948078 @default.
- W4382562503 hasConceptScore W4382562503C29730261 @default.
- W4382562503 hasConceptScore W4382562503C43554185 @default.
- W4382562503 hasConceptScore W4382562503C55493867 @default.
- W4382562503 hasConceptScore W4382562503C71924100 @default.
- W4382562503 hasConceptScore W4382562503C86803240 @default.
- W4382562503 hasConceptScore W4382562503C98274493 @default.
- W4382562503 hasIssue "1" @default.
- W4382562503 hasLocation W43825625031 @default.
- W4382562503 hasOpenAccess W4382562503 @default.
- W4382562503 hasPrimaryLocation W43825625031 @default.
- W4382562503 hasRelatedWork W1592261125 @default.
- W4382562503 hasRelatedWork W1982027601 @default.
- W4382562503 hasRelatedWork W2073235663 @default.
- W4382562503 hasRelatedWork W2099136586 @default.
- W4382562503 hasRelatedWork W2109994537 @default.
- W4382562503 hasRelatedWork W2350027679 @default.
- W4382562503 hasRelatedWork W2416964709 @default.
- W4382562503 hasRelatedWork W2464301138 @default.
- W4382562503 hasRelatedWork W2517050254 @default.
- W4382562503 hasRelatedWork W2188252428 @default.
- W4382562503 hasVolume "2" @default.
- W4382562503 isParatext "false" @default.
- W4382562503 isRetracted "false" @default.
- W4382562503 workType "article" @default.